## 1 Introduction
\begin{table}
\begin{tabular}{c c c c c c c c} \hline \hline
**Drug 1** & **Dose** **(mg)** & **I\({}_{\text{max}}\) (\#M) 2** & **I\({}_{\text{in},\text{max}}\) (\#M) 2** & **f\({}_{\text{U}}\) 2** & **I\({}_{\text{in},\text{max},\text{u}}\) (\#M) 2** & **IC\({}_{\text{50}}\)** & **R 4** \\ \hline Nifedipine 5 & 10 [21] & 0.23 [21] & 2.02 & 0.0045 [21] & 0.009 & 91 & 1.00 \\ Nimodipine 5 & 30 [32] & 0.11 [32] & 4.56 & 0.02 [13] & 0.091 & 276 & 1.00 \\ Nitrendipine 5 & 20 [33] & 0.12 [33] & 3.56 & 0.02 [13] & 0.071 & 161 & 1.00 \\ Olmesartan 5 & 160 [24] & 3.8 [24] & 26.1 & 0.01 [24] & 0.261 & 339 & 1.00 \\ Pioglitzazone 5 & 30 [23] & 4.2 [23] & 9.44 & 0.009 [23] & 0.084 & 5.8 & 1.01 \\ Probencid 5 & 2000 [34] & 520.8 [34] & 956.1 & 0.12 [13] & 114.7 & 791 & 1.14 \\ Propranolol & 105 [21] & 0.52 [21] & 25.7 & 0.1 [21] & 2.57 & 6 [22] & 1.43 \\ Propranolol & 80 [23] & 0.19 [23] & 19.4 & 0.13 [23] & 2.51 & 6 [22] & 1.42 \\ Raloxifene 5 & 60 [24] & 0.003 [24] & 7.87 & 0.05 [24] & 0.394 & 438 & 1.00 \\ Rifampicin 5 & 600 [23] & 7.9 [23] & 53.2 & 0.3 [23] & 16.0 & 605 & 1.00 \\ Ritonavir & 600 [21] & 15.5 [21] & 67.2 & 0.006 [21] & 0.403 & 2 [26] & 1.20 \\ Ritonavir & 600 [23] & 15.3 [23] & 66.9 & 0.015 [23] & 1.0 & 2 [26] & 1.50 \\ Rosiglitzazone & 8 [35] & 1.7 [35] & 3.1 & 0.01 [13] & 0.031 & 5.1 [35] & 1.01 \\ Rosuvastatin 5 & 20 [36] & 0.01 [36] & 2.6 & 0.17 [37] & 0.441 & 186 & 1.00 \\ Saquinavir & 400 [23] & 7.6 [23] & 44.6 & 0.02 [23] & 0.892 & 7 [26] & 1.13 \\ Simvastatin 5 & 80 [24] & 0.10 [24] & 12.0 & 0.06 [24] & 0.718 & 70 & 1.01 \\ Sulfasalazine & 1000 [35] & 15.0 [35] & 170.9 & 0.05 [24] & 8.5 & 9.6 [35] & 1.89 \\ Telmisartan 5 & 80 [23] & 1.2 [23] & 10.9 & 0.005 [23] & 0.054 & 87 & 1.00 \\ Zafirlukast & 20 [35] & 0.6 [35] & 2.8 & 0.01 [24] & 0.028 & 6.5 [35] & 1.00 \\ \hline \hline \end{tabular}  
* Drugs are given orally except for budesonide and bulevirtide, which are inhaled and administered subcutaneously, respectively. Data for dose, I\({}_{\text{max}}\), f\({}_{\text{U}}\), and IC\({}_{\text{50}}\) are from the references indicated in brackets. 2 Calculated in this study according to [PERSON] et al. [21] and FDA guidance [38]. I\({}_{\text{max}}\): plasma concentration after a single dose: I\({}_{\text{max}}\): estimated maximum inhibitor concentration at the inlet of the liver based on equation I\({}_{\text{in},\text{max}}\) = I\({}_{\text{max}}\) + (F\({}_{\text{x}}\) \(\times\) F\({}_{\text{g}}\) \(\times\) K\({}_{\text{x}}\) \(\times\) Dose)/Q\({}_{\text{h}}\)/R with F\({}_{\text{x}}\) (fraction absorbed) \(>\) 1. \(\text{F}_{\text{g}}\) (intestinal availability) \(>\) 1. \(\text{k}_{\text{x}}\) (absorption rate constant) \(\text{=}\) 0.1/min. Q\({}_{\text{h}}\) (hepatic blood flow rate) \(\text{=}\) 1616.7 mL/min. RB (blood-plasma ratio) \(\text{=}\) 1; I\({}_{\text{in},\text{max},\text{u}}\): estimated free maximum inhibitor concentration at the inlet of the liver based on equation I\({}_{\text{in},\text{max},\text{u}}\) = I\({}_{\text{in},\text{max},\text{u}}\) \(\times\) f\({}_{\text{u}}\) with f\({}_{\text{g}}\): fraction unbound. 3 Murouchard used as substrate, except for gemfropsi, where roussertain was used. 4 R = (1 + (I\({}_{\text{in},\text{max}}\))/IC\({}_{\text{50}}\)). Drugs with a cutoff of R \(\geq\) 1.1 are potential clinical inhibitors according to FDA guidelines [38] and are marked in gray. 5 IC\({}_{\text{50}}\) values calculated in this study from K\({}_{\text{i}}\) values based on equation IC\({}_{\text{50}}\) = K\({}_{\text{i}}\)\(\times\) (1 + [S]/K\({}_{\text{nn}}\)) [39] with [S] = 10 uM tauroucholate and K\({}_{\text{nn}}\) = 22 uM [40].  
\end{table} 
Table 1: _Cont._As shown by [PERSON] et al. [54], polymorphisms that alter NTCP transport function are also critical for viral entry, indicating that molecular mechanisms important for HBV/HDV entry overlap with those for bile salts uptake. Of note, the p.S267F variant has been shown to be protective against HBV/HDV infection and was associated with a reduced risk of developing advanced liver cancer [55].